Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Setmelanotide

Stage Phase 3Stale

Sponsor Rhythm Pharmaceuticals, Inc

Route injection

Class MC4R

Mechanism EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

Sources

registry, as of 2026-08-06Stale

https://clinicaltrials.gov/study/NCT05093634

EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway. Overall status COMPLETED. Phases PHASE3. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 296. Conditions Obesity; Genetic Obesity. The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in patients with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway: * POMC or PCSK1 (Sub-study 035a) * LEPR (Sub-

ClinicalTrials.gov NCT05093634 protocol and results modules

registry, as of 2025-05-31Stale

https://clinicaltrials.gov/study/NCT03651765

Long Term Extension Trial of Setmelanotide. Overall status COMPLETED. Phases PHASE2,PHASE3. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 205. Conditions Obesity Associated With Defects in Leptin-melanocortin Pathway. This was a long-term extension trial to study the safety and tolerability of continued setmelanotide treatment in participants who had completed a previous clinical trial on treatment with setmelanotide for obesity associated with genetic defects upstream of the Melanocortin-4 (M deaths Setmelanotide 0 nausea Setmelanotide 28 vomiting Setmelanotide 21 diarrhoea Setmelanotide 17

ClinicalTrials.gov NCT03651765 protocol and results modules

registry, as of 2026-08-10Stale

https://clinicaltrials.gov/study/NCT05774756

A Trial of Setmelanotide in Acquired Hypothalamic Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 143. Conditions Hypothalamic Obesity. The goal of this trial is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with acquired Hypothalamic Obesity (HO). To determine how well setmelanotide works and how safe it is, patients with HO wi Pivotal Cohort: Percentage of Participants With a ≥10% Reduction From Baseline in Body Weight Setmelanotide 55.6 Pivotal Cohort: Percentage of Participants With a ≥10% Reduction From Baseline in Body Weight Placebo 0.05 deaths Setmelanotide 2 nausea Setmelanotide 49 vomiting Setmelanotide 36 diarrhoea Setmelanotide 19 deaths Placebo 0 nausea Placebo 17 vomiting Placebo 14 diarrhoea Placebo 14

ClinicalTrials.gov NCT05774756 protocol and results modules

registry, as of 2023-12-01Stale

https://clinicaltrials.gov/study/NCT03746522

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 52. Conditions Bardet Biedl Syndrome (BBS); Alström Syndrome (AS). This pivotal, phase 3 study is designed to confirm the efficacy and safety of setmelanotide, a potent melanocortin receptor type 4 (MC4R) agonist, for the treatment of obesity and hyperphagia in participants with Bardet Biedl syndrome (BBS) or Alström syndrome (AS). The study's p Percentage of Participants (≥12 Years of Age at Baseline) Who Reached ≥10% Weight Loss Threshold After 1 Year (Period 2): Pivotal Cohort Pivotal Cohort 32.3 Mean Percent Change From Baseline in Body Weight (≥12 Years of Age) at Week 52 (Period 2): Pivotal Cohort Pivotal Cohort -5.21 percen

ClinicalTrials.gov NCT03746522 protocol and results modules

registry, as of 2026-02-12Stale

https://clinicaltrials.gov/study/NCT06760546

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756). Overall status RECRUITING. Phases PHASE3. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 39. Conditions Hypothalamic Obesity; Multiple Pituitary Hormone Deficiency Genetic Form; Septo-Optic Dysplasia; Optic Nerve Hypoplasia; Childhood-onset Combined Pituitary Hormone Deficiency; Pitu. This is a sub-study of Study RM-493-040 (NCT05774756). The goal of this sub-study is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with congenital Hypothalamic Obesity (cHO). To determine how w

ClinicalTrials.gov NCT06760546 protocol and results modules

registry, as of 2026-07-15Stale

https://clinicaltrials.gov/study/NCT06596135

Open-Label Extension Study of Setmelanotide. Overall status COMPLETED. Phases PHASE3. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 28. Conditions Obesity Associated With Defects in Leptin-melanocortin Pathway. This is an open-label extension study designed to evaluate the long-term safety and tolerability of continued setmelanotide treatment in male and female patients ≥2 years of age who have completed or transitioned from a previous study with setmelanotide for rare genetic, syndromi

ClinicalTrials.gov NCT06596135 protocol and results modules

registry, as of 2024-11-26Stale

https://clinicaltrials.gov/study/NCT05194124

Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway. Overall status COMPLETED. Phases PHASE3. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 19. Conditions Bardet-Biedl Syndrome; POMC Deficiency. A trial to compare the weekly and daily formulations of setmelanotide in participants with genetic defects in the melanocortin-4 receptor pathway. deaths Run-in Period: Setmelanotide 2 mg QD 0 diarrhoea Run-in Period: Setmelanotide 2 mg QD 0 nausea Run-in Period: Setmelanotide 2 mg QD 0 vomiting Run-in Period: Setmelanotide 2 mg QD 0 deaths Run-in Period: Setmelanotide 2.5 mg QD 0 diarrhoea Run-in Period: Setmelanotide 2.5 mg QD 0 nausea Run-in Period: Setmelanotide 2.5 mg QD 0 vomiting Run-in Period: Setmelanotide 2.5 mg QD 0 deaths Run-in Period: Setmelanotide 3 mg QD 0 diarrhoea Run-in Period: Setmelanotide 3 mg QD

ClinicalTrials.gov NCT05194124 protocol and results modules

registry, as of 2023-05-23Stale

https://clinicaltrials.gov/study/NCT03287960

Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 15. Conditions Leptin Receptor Deficiency Obesity. To demonstrate statistically significant and clinically meaningful effects of setmelanotide on percent body weight change in participants with LEPR deficiency obesity due to rare bi-allelic or loss-of function mutations at the end of 1 year of treatment. Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) Setmelanotide (Entire Study) 45.5 Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal + Supplemental Cohort) Setmelanotide (Entire Study) 53.3 Mean Percent Change From Baseline in Body Weight Setmelanotide (Entire Study) -12.34 Percent change Baseline and Week 52 deaths Setmelanotide 1 na

ClinicalTrials.gov NCT03287960 protocol and results modules

registry, as of 2023-09-21Stale

https://clinicaltrials.gov/study/NCT02896192

Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 15. Conditions Pro-opiomelanocortin (POMC) Deficiency Obesity. To demonstrate statistically significant and clinically meaningful effects of setmelanotide on percent body weight change in participants with pro-opiomelanocortin (POMC) deficiency or proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency obesity due to rare biallelic Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) Setmelanotide (Entire Study) 80.0 Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal + Supplemental Cohort) Setmelanotide (Entire Study) 85.7 Mean Percent Change From Baseline in Body Weight at Week 52 Setmelanotide (Entire Study) -25

ClinicalTrials.gov NCT02896192 protocol and results modules

registry, as of 2024-11-27Stale

https://clinicaltrials.gov/study/NCT04966741

Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 12. Conditions Bardet-Biedl Syndrome; POMC Deficiency Obesity; PCSK1 Deficiency Obesity; LEPR Deficiency Obesity. This is a phase 3 open-label, clinical study to evaluate the efficacy, safety and tolerability of setmelanotide over 1 year of treatment, in pediatric participants aged 2 to \<6 years with obesity due to either biallelic variants of the pro-opiomelanocortin (POMC), proprotein con deaths Setmelanotide: PPL Group 0 vomiting Setmelanotide: PPL Group 4 diarrhoea Setmelanotide: PPL Group 2 deaths Setmelanotide: BBS Group 0 vomiting Setmelanotide: BBS Group 3 diarrhoea Setmelanotide: BBS Group 0

ClinicalTrials.gov NCT04966741 protocol and results modules

registry, as of 2023-08-18Stale

https://clinicaltrials.gov/study/NCT03013543

Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity. Overall status COMPLETED. Phases PHASE2. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 213. Conditions Genetic Obesity; Obesity; Obesity Due to Melanocortin 4 Receptor Deficiency. The purpose of the study was to determine the effect of setmelanotide (RM-493) on weight, hunger assessments, and other factors in participants with rare genetic disorders of obesity. Percent Change From Baseline in Body Weight After 3 Months of Setmelanotide Treatment 16p11.2 Cohort -2.19 percent change Baseline, Month 3 Percent Change From Baseline in Body Weight After 3 Months of Setmelanotide Treatment AS Cohort -6.38 percent change Baseline, Month 3 Percent Change From Baseline in Body Weight After 3 Months of Setmelanotide Treatment BBS Cohort -4.19 percent change Baseline, Month 3 Percent Change From Bas

ClinicalTrials.gov NCT03013543 protocol and results modules

registry, as of 2025-07-02Stale

https://clinicaltrials.gov/study/NCT04963231

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway. Overall status COMPLETED. Phases PHASE2. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 164. Conditions Genetic Obesity. The purpose of this study was to evaluate the safety and efficacy of once daily subcutaneous (SC) administration of setmelanotide in participants with obesity and specific gene variants in the MC4R pathway. Percent Change in Body Weight From Baseline to the End of Stage 1 in Participants ≥18 Years Old, Per Genotype Overall: Change at Week 16 Stage 1: Setmelanotide (Open-Label) -3.94 percent change Baseline, Week 16 Percent Change in Body Weight From Baseline to the End of Stage 1 in Participants ≥18 Years Old, Per Genotype Gene: NRP2, Change at Week 16 Stage 1: Setmelanotide (Open-Label) -1.37 percent change Baseline, Week 16 Percent Chan

ClinicalTrials.gov NCT04963231 protocol and results modules

registry, as of 2023-08-07Stale

https://clinicaltrials.gov/study/NCT02041195

Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 99. Conditions Overweight and Obesity. The purpose of this study is to evaluate the effects of a new daily subcutaneous (SC) injectable formulation of setmelanotide (RM-493) in healthy participants with obesity on mean percent body weight loss and other weight loss parameters, as well as pharmacokinetic (PK) profile. deaths Stage A: Placebo 0.75 mg BID 0 nausea Stage A: Placebo 0.75 mg BID 0 vomiting Stage A: Placebo 0.75 mg BID 0 diarrhoea Stage A: Placebo 0.75 mg BID 0 deaths Stage A: Placebo 1.5 mg QD 0 nausea Stage A: Placebo 1.5 mg QD 1 vomiting Stage A: Placebo 1.5 mg QD 0 diarrhoea Stage A: Placebo 1.5 mg QD 0 deaths Stage B: Placebo 1.5 mg QD 0 nausea Stage B: Placebo 1.5 mg QD 1 vomiting Stage

ClinicalTrials.gov NCT02041195 protocol and results modules

registry, as of 2023-08-14Stale

https://clinicaltrials.gov/study/NCT01749137

Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants. Overall status COMPLETED. Phases PHASE2. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 74. Conditions Overweight. The purpose of this study is to evaluate the effects of RM-493 on mean percent body weight loss, and other weight loss parameters as well as Pharmacokinetic (PK) profile, and ambulatory blood pressure in obese participants. The study is designed to evaluate the efficacy and toler Percent Change From Baseline in Body Weight Setmelanotide -2.0 Percent change Baseline and Day 90 Percent Change From Baseline in Body Weight Placebo -0.3 Percent change Baseline and Day 90 Percentage of Participants Who Lost ≥ 5% of Their Baseline Body Weight Setmelanotide 9.1 Percentage of Participants Who Lost ≥ 5% of Their Baseline Body Weight Placebo 5.6 Percent Change From Baseline in Body Weight in Severely

ClinicalTrials.gov NCT01749137 protocol and results modules

registry, as of 2023-07-27Stale

https://clinicaltrials.gov/study/NCT02311673

Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome. Overall status COMPLETED. Phases PHASE2. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 40. Conditions Prader-Willi Syndrome. The purpose of this study was to evaluate the effects of a once daily subcutaneous injectable formulation of setmelanotide in obese participants with Prader-Willi syndrome on tolerability, weight loss, and hyperphagia-related behavior. The study drug (setmelanotide and placebo) w Percent Change From Baseline in Body Weight - Period 4 Setmelanotide 1.5 mg (Open-Label Extension) -0.0 percent change Baseline (Day 56) and Day 70 Percent Change From Baseline in Body Weight - Period 4 Setmelanotide 2.5 mg (Open-Label Extension) 0.0 percent change Baseline (Day 56) and Day 70 deaths Setmelanotide 0.5 mg (Double-blind Randomized Treatment) 0 nau

ClinicalTrials.gov NCT02311673 protocol and results modules

Studies

EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

Registry NCT05093634

Phase Phase 3

Status Completed

Enrollment 296

Start 2021-12-10

Primary completion 2025-12-22

Study completion 2026-06-30

Catalyst Primary completion. 2025-12-22. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

POMC or PCSK1 variant

Population Obesity; Genetic Obesity

LEPR variant

Population Obesity; Genetic Obesity

NCOA1 (SRC1) variant

Population Obesity; Genetic Obesity

SH2B1 variant

Population Obesity; Genetic Obesity

Long Term Extension Trial of Setmelanotide

Registry NCT03651765

EudraCT 2017-005006-35

Phase Phase 2/3

Status Completed

Enrollment 205

Start 2018-07-15

Primary completion 2025-01-09

Study completion 2025-01-09

Catalyst Primary completion. 2025-01-09. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Setmelanotide

Regimen once daily

Population Obesity Associated With Defects in Leptin-melanocortin Pathway

deaths

participants with nausea, 28 participantsStale

participants with vomiting, 21 participantsStale

participants with diarrhoea, 17 participantsStale

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

Registry NCT05774756

Phase Phase 3

Status Active, not recruiting

Enrollment 143

Start 2023-04-26

Primary completion 2025-03-18

Study completion 2027-04-16

Catalyst Primary completion. 2025-03-18. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Setemelanotide

Regimen daily

Weeks 52

Comparator placebo

Population Hypothalamic Obesity

Placebo

Regimen daily

Weeks 52

Population Hypothalamic Obesity

participants with at least 10 percent body weight loss, 0.05 %, week 52Stale

deaths

participants with nausea, 17 participantsStale

participants with vomiting, 14 participantsStale

participants with diarrhoea, 14 participantsStale

Setmelanotide

Regimen daily

Weeks 52

Population Hypothalamic Obesity

participants with at least 10 percent body weight loss, 55.6 %, week 52Stale

deaths

participants with nausea, 49 participantsStale

participants with vomiting, 36 participantsStale

participants with diarrhoea, 19 participantsStale

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

Registry NCT03746522

EudraCT 2018-004058-11

Phase Phase 3

Status Completed

Enrollment 52

Start 2018-11-23

Primary completion 2020-11-16

Study completion 2021-03-08

Setmelanotide (Double-Blind)

Regimen once daily

Weeks 52

Comparator placebo

Population Bardet Biedl Syndrome (BBS); Alström Syndrome (AS)

deaths

participants with nausea, 7 participantsStale

participants with vomiting, 7 participantsStale

participants with diarrhoea, 2 participantsStale

Placebo (Double-Blind)

Regimen once daily

Weeks 52

Population Bardet Biedl Syndrome (BBS); Alström Syndrome (AS)

deaths

participants with nausea, 6 participantsStale

participants with vomiting, 0 participantsStale

participants with diarrhoea, 1 participantsStale

Setmelanotide (Open-label)

Regimen once daily

Weeks 52

Comparator placebo

Population Bardet Biedl Syndrome (BBS); Alström Syndrome (AS)

deaths

participants with nausea, 8 participantsStale

participants with vomiting, 8 participantsStale

participants with diarrhoea, 7 participantsStale

Pivotal Cohort

Regimen once daily

Weeks 52

Population Bardet Biedl Syndrome (BBS); Alström Syndrome (AS)

participants with at least 10 percent body weight loss, 32.3 %, week 52Stale

percent change in body weight, -5.21 %, week 52Stale

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

Registry NCT06760546

Phase Phase 3

Status Recruiting

Enrollment 39

Start 2025-09-23

Primary completion 2027-03-13

Study completion 2028-03-13

Catalyst Primary completion. 2027-03-13. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Setemelanotide

Regimen daily

Weeks 26

Comparator placebo

Population Hypothalamic Obesity; Multiple Pituitary Hormone Deficiency Genetic Form; Septo-Optic Dysplasia; Optic Nerve Hypoplasia; Childhood-onset Combined Pituitary Hormone Deficiency; Pitu

Placebo

Regimen daily

Weeks 26

Population Hypothalamic Obesity; Multiple Pituitary Hormone Deficiency Genetic Form; Septo-Optic Dysplasia; Optic Nerve Hypoplasia; Childhood-onset Combined Pituitary Hormone Deficiency; Pitu

Open-Label Extension Study of Setmelanotide

Registry NCT06596135

Phase Phase 3

Status Completed

Enrollment 28

Start 2024-10-21

Primary completion 2026-06-24

Study completion 2026-06-24

Catalyst Primary completion. 2026-06-24. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Setelanotide (Open-label)

Regimen once daily

Population Obesity Associated With Defects in Leptin-melanocortin Pathway

Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

Registry NCT05194124

Phase Phase 3

Status Completed

Enrollment 19

Start 2021-12-21

Primary completion 2023-10-19

Study completion 2023-10-19

Run-in Period: Setmelanotide 2 mg QD

Dose 2 mg

Regimen once daily

Weeks 1

Population Bardet-Biedl Syndrome; POMC Deficiency

deaths

participants with diarrhoea, 0 participantsStale

participants with nausea, 0 participantsStale

participants with vomiting, 0 participantsStale

Run-in Period: Setmelanotide 2.5 mg QD

Dose 2.5 mg

Regimen once weekly

Weeks 1

Population Bardet-Biedl Syndrome; POMC Deficiency

deaths

participants with diarrhoea, 0 participantsStale

participants with nausea, 0 participantsStale

participants with vomiting, 0 participantsStale

Run-in Period: Setmelanotide 3 mg QD

Dose 3 mg

Regimen once weekly

Weeks 1

Population Bardet-Biedl Syndrome; POMC Deficiency

deaths

participants with diarrhoea, 0 participantsStale

participants with nausea, 0 participantsStale

participants with vomiting, 0 participantsStale

DB Period: Setmelanotide 20 mg QW

Dose 20 mg

Regimen once weekly

Weeks 1

Population Bardet-Biedl Syndrome; POMC Deficiency

deaths

participants with diarrhoea, 0 participantsStale

participants with nausea, 0 participantsStale

participants with vomiting, 0 participantsStale

DB Period: Setmelanotide 25 mg QW

Dose 25 mg

Regimen once weekly

Weeks 1

Population Bardet-Biedl Syndrome; POMC Deficiency

deaths

participants with diarrhoea, 0 participantsStale

participants with nausea, 1 participantsStale

participants with vomiting, 0 participantsStale

DB Period: Setmelanotide 3 mg QD

Dose 3 mg

Regimen once weekly

Weeks 1

Population Bardet-Biedl Syndrome; POMC Deficiency

deaths

participants with diarrhoea, 2 participantsStale

participants with nausea, 3 participantsStale

participants with vomiting, 2 participantsStale

DB Period: Setmelanotide 30 mg QW

Dose 30 mg

Regimen once weekly

Weeks 1

Population Bardet-Biedl Syndrome; POMC Deficiency

deaths

participants with diarrhoea, 0 participantsStale

participants with nausea, 0 participantsStale

participants with vomiting, 0 participantsStale

OL Period: Setmelanotide 20 mg QW

Dose 20 mg

Regimen once weekly

Weeks 1

Population Bardet-Biedl Syndrome; POMC Deficiency

deaths

participants with diarrhoea, 0 participantsStale

participants with nausea, 0 participantsStale

participants with vomiting, 0 participantsStale

OL Period: Setmelanotide 25 mg QW

Dose 25 mg

Regimen once weekly

Weeks 1

Population Bardet-Biedl Syndrome; POMC Deficiency

deaths

participants with diarrhoea, 0 participantsStale

participants with nausea, 1 participantsStale

participants with vomiting, 0 participantsStale

OL Period: Setmelanotide 30 mg QW

Dose 30 mg

Regimen once weekly

Weeks 1

Population Bardet-Biedl Syndrome; POMC Deficiency

deaths

participants with diarrhoea, 2 participantsStale

participants with nausea, 0 participantsStale

participants with vomiting, 1 participantsStale

Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity

Registry NCT03287960

EudraCT 2017-002005-36

Phase Phase 3

Status Completed

Enrollment 15

Start 2018-01-30

Primary completion 2020-09-25

Study completion 2020-09-25

Setmelanotide

Regimen once daily

Weeks 12

Population Leptin Receptor Deficiency Obesity

participants with at least 10 percent body weight loss, 45.5 %, week 52Stale

percent change in body weight, -12.34 %, week 52Stale

deaths

participants with nausea, 8 participantsStale

participants with diarrhea, 7 participantsStale

participants with vomiting, 2 participantsStale

Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity

Registry NCT02896192

EudraCT 2016-002320-83

Phase Phase 3

Status Completed

Enrollment 15

Start 2017-02-14

Primary completion 2020-05-25

Study completion 2020-05-25

Setmelanotide

Regimen once daily

Weeks 12

Population Pro-opiomelanocortin (POMC) Deficiency Obesity

participants with at least 10 percent body weight loss, 80 %, week 52Stale

percent change in body weight, -25.83 %, week 52Stale

deaths

participants with nausea, 8 participantsStale

participants with vomiting, 8 participantsStale

participants with diarrhoea, 5 participantsStale

Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity

Registry NCT04966741

Phase Phase 3

Status Completed

Enrollment 12

Start 2022-03-08

Primary completion 2023-09-18

Study completion 2024-11-08

Setmelanotide: PPL Group

Regimen once daily

Weeks 2

Population Bardet-Biedl Syndrome; POMC Deficiency Obesity; PCSK1 Deficiency Obesity; LEPR Deficiency Obesity

deaths

participants with vomiting, 4 participantsStale

participants with diarrhoea, 2 participantsStale

Setmelanotide: BBS Group

Regimen once daily

Weeks 2

Population Bardet-Biedl Syndrome; POMC Deficiency Obesity; PCSK1 Deficiency Obesity; LEPR Deficiency Obesity

deaths

participants with vomiting, 3 participantsStale

participants with diarrhoea, 0 participantsStale

Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity

Registry NCT03013543

EudraCT 2017-000387-14

Phase Phase 2

Status Completed

Enrollment 213

Start 2017-02-10

Primary completion 2022-03-01

Study completion 2022-03-01

16p11.2 Cohort

Regimen once daily

Weeks 16

Population Genetic Obesity; Obesity; Obesity Due to Melanocortin 4 Receptor Deficiency

percent change in body weight, -2.19 %Stale

deaths

participants with nausea, 9 participantsStale

participants with vomiting, 1 participantsStale

participants with diarrhoea, 1 participantsStale

AS Cohort

Regimen once daily

Weeks 16

Population Genetic Obesity; Obesity; Obesity Due to Melanocortin 4 Receptor Deficiency

percent change in body weight, -6.38 %Stale

deaths

participants with nausea, 1 participantsStale

participants with vomiting, 0 participantsStale

participants with diarrhoea, 0 participantsStale

BBS Cohort

Regimen once daily

Weeks 16

Population Genetic Obesity; Obesity; Obesity Due to Melanocortin 4 Receptor Deficiency

percent change in body weight, -4.19 %Stale

deaths

participants with nausea, 3 participantsStale

participants with vomiting, 2 participantsStale

participants with diarrhoea, 2 participantsStale

MC4R Cohort

Regimen once daily

Weeks 16

Population Genetic Obesity; Obesity; Obesity Due to Melanocortin 4 Receptor Deficiency

percent change in body weight, -0.75 %Stale

deaths

participants with nausea, 12 participantsStale

participants with vomiting, 7 participantsStale

participants with diarrhoea, 7 participantsStale

POMC/PCSK1/LEPR Heterozygous Cohort

Regimen once daily

Weeks 16

Population Genetic Obesity; Obesity; Obesity Due to Melanocortin 4 Receptor Deficiency

percent change in body weight, -3.5 %Stale

deaths

participants with nausea, 14 participantsStale

participants with vomiting, 4 participantsStale

participants with diarrhoea, 3 participantsStale

POMC/PCSK1/LEPR Composite Heterozygous Cohort

Regimen once daily

Weeks 16

Population Genetic Obesity; Obesity; Obesity Due to Melanocortin 4 Receptor Deficiency

percent change in body weight, -0.31 %Stale

deaths

participants with nausea, 4 participantsStale

participants with vomiting, 2 participantsStale

participants with diarrhoea, 0 participantsStale

POMC/PCSK1/LEPR Compound Heterozygous Cohort

Regimen once daily

Weeks 16

Population Genetic Obesity; Obesity; Obesity Due to Melanocortin 4 Receptor Deficiency

percent change in body weight, -5.57 %Stale

deaths

participants with nausea, 13 participantsStale

participants with vomiting, 6 participantsStale

participants with diarrhoea, 1 participantsStale

SH2B1 Cohort

Regimen once daily

Weeks 16

Population Genetic Obesity; Obesity; Obesity Due to Melanocortin 4 Receptor Deficiency

percent change in body weight, -2.92 %Stale

deaths

participants with nausea, 13 participantsStale

participants with vomiting, 6 participantsStale

participants with diarrhoea, 4 participantsStale

SMS Cohort

Regimen once daily

Weeks 16

Population Genetic Obesity; Obesity; Obesity Due to Melanocortin 4 Receptor Deficiency

percent change in body weight, 0 %Stale

deaths

participants with nausea, 2 participantsStale

participants with vomiting, 0 participantsStale

participants with diarrhoea, 4 participantsStale

SRC1 Cohort

Regimen once daily

Weeks 16

Population Genetic Obesity; Obesity; Obesity Due to Melanocortin 4 Receptor Deficiency

percent change in body weight, -3.34 %Stale

deaths

participants with nausea, 11 participantsStale

participants with vomiting, 4 participantsStale

participants with diarrhoea, 1 participantsStale

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

Registry NCT04963231

Phase Phase 2

Status Completed

Enrollment 164

Start 2021-11-30

Primary completion 2023-08-04

Study completion 2024-09-30

Stage 1: Setmelanotide (Open-Label)

Regimen once daily

Weeks 16

Comparator placebo

Population Genetic Obesity

percent change in body weight, -3.94 %, week 16Stale

deaths

participants with nausea, 75 participantsStale

participants with vomiting, 41 participantsStale

participants with diarrhoea, 22 participantsStale

Stage 2: Setmelanotide (Double-Blind)

Regimen once daily

Weeks 16

Comparator placebo

Population Genetic Obesity

deaths

participants with nausea, 4 participantsStale

participants with vomiting, 3 participantsStale

participants with diarrhoea, 2 participantsStale

Stage 2: Placebo (Double-Blind)

Regimen once daily

Weeks 16

Population Genetic Obesity

deaths

participants with nausea, 0 participantsStale

participants with vomiting, 0 participantsStale

participants with diarrhoea, 0 participantsStale

Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients

Registry NCT02041195

Phase Phase 1/2

Status Completed

Enrollment 99

Setmelanotide Once Daily

Regimen once daily

Comparator placebo

Population Overweight and Obesity

Setmelanotide Split Dose

Regimen once daily

Comparator placebo

Population Overweight and Obesity

Placebo

Regimen once daily

Population Overweight and Obesity

deaths

participants with nausea, 0 participantsStale

participants with vomiting, 0 participantsStale

participants with diarrhoea, 0 participantsStale

Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants

Registry NCT01749137

Phase Phase 2

Status Completed

Enrollment 74

Start 2013-01-14

Primary completion 2013-09-28

Study completion 2013-09-28

Setmelanotide

Regimen daily

Comparator placebo

Population Overweight

percent change in body weight, -2 %Stale

participants with at least 5 percent body weight loss, 9.1 %Stale

deaths

participants with nausea, 5 participantsStale

participants with vomiting, 0 participantsStale

participants with diarrhoea, 1 participantsStale

Placebo

Regimen daily

Population Overweight

percent change in body weight, -0.3 %Stale

participants with at least 5 percent body weight loss, 5.6 %Stale

deaths

participants with nausea, 3 participantsStale

participants with vomiting, 2 participantsStale

participants with diarrhoea, 0 participantsStale

Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome

Registry NCT02311673

Phase Phase 2

Status Completed

Enrollment 40

Start 2015-03-19

Primary completion 2016-10-26

Study completion 2016-10-26

Setmelanotide 0.5 mg

Dose 0.5 mg

Regimen once daily

Comparator placebo

Population Prader-Willi Syndrome

deaths

participants with nausea, 0 participantsStale

Setmelanotide 1.5 mg

Dose 1.5 mg

Regimen once daily

Comparator placebo

Population Prader-Willi Syndrome

percent change in body weight, 0 %Stale

deaths

participants with nausea, 0 participantsStale

Setmelanotide 2.5 mg

Dose 2.5 mg

Regimen once daily

Comparator placebo

Population Prader-Willi Syndrome

percent change in body weight, 0 %Stale

deaths

participants with nausea, 0 participantsStale

Placebo

Regimen once daily

Population Prader-Willi Syndrome

deaths

participants with nausea, 1 participantsStale